Caladrius Biosciences (CLBS) & Its Rivals Head to Head Contrast
Caladrius Biosciences (NASDAQ: CLBS) is one of 180 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Caladrius Biosciences to related businesses based on the strength of its dividends, profitability, valuation, risk, earnings, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Caladrius Biosciences and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Caladrius Biosciences||$35.28 million||-$32.65 million||-1.59|
|Caladrius Biosciences Competitors||$217.29 million||-$39.39 million||-11.26|
Institutional and Insider Ownership
6.4% of Caladrius Biosciences shares are held by institutional investors. Comparatively, 48.2% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 13.1% of Caladrius Biosciences shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Caladrius Biosciences and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Caladrius Biosciences Competitors||542||2431||6527||128||2.65|
Caladrius Biosciences presently has a consensus target price of $7.00, indicating a potential upside of 112.12%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.18%. Given Caladrius Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Caladrius Biosciences is more favorable than its peers.
Volatility and Risk
Caladrius Biosciences has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, Caladrius Biosciences’ peers have a beta of 1.54, indicating that their average stock price is 54% more volatile than the S&P 500.
This table compares Caladrius Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Caladrius Biosciences Competitors||-4,404.85%||-490.59%||-40.74%|
Caladrius Biosciences beats its peers on 7 of the 12 factors compared.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.